Payment overview · 2025
General Payments
$136.86
8 reported records · 5 companies
Healthcare provider profile · identity verified
Ramel Failma, MD
Allopathic & Osteopathic Physicians|Family Medicine · PERRY, FL · NPI 1457361180
Verified facts
What the public records show
CMS Open Payments records show Ramel Failma, MD received $136.86 in general payments during 2025 across 8 reported records.
Merck Sharp & Dohme LLC accounted for 40.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 7 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Entresto, Farxiga.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 73 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 32 claims for Symbicort by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Entresto by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $54.74 | 40.0% | 3 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $35.92 | 26.2% | 2 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $17.38 | 12.7% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $14.46 | 10.6% | 1 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $14.36 | 10.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $136.86 | 8 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| VERQUVO Normalized: verquvo |
Drug | Merck Sharp & Dohme LLC | $41.21 | 2 | 2025 |
Source payment records
|
|||||
| ENTRESTO Normalized: entresto |
Drug | Novartis Pharmaceuticals Corporation | $35.92 | 2 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $35.92 | 2 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $17.38 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $14.46 | 1 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $14.36 | 1 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $13.53 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ENTRESTO entresto |
2025 | Entresto | 2024 | 15 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 73 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
73 | 18 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
32 | suppressed by CMS |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 545 | 153 |
| Omeprazole | Omeprazole | 222 | 67 |
| Metformin Hcl | Metformin Hcl | 186 | 52 |
| Furosemide | Furosemide | 184 | 44 |
| Gabapentin | Gabapentin | 180 | 39 |
| Amlodipine Besylate | Amlodipine Besylate | 171 | 44 |
| Levothyroxine Sodium | Levothyroxine Sodium | 153 | 40 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 141 | 25 |
| Lisinopril | Lisinopril | 137 | 39 |
| Losartan Potassium | Losartan Potassium | 135 | 41 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 125 | 22 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 114 | 22 |
| Quetiapine Fumarate | Quetiapine Fumarate | 110 | 21 |
| Tamsulosin Hcl | Tamsulosin Hcl | 103 | 29 |
| Fluticasone Propionate | Fluticasone Propionate | 101 | 34 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 99 | 27 |
| Pioglitazone Hcl | Pioglitazone Hcl | 99 | 27 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 92 | 23 |
| Simvastatin | Simvastatin | 88 | 19 |
| Zolpidem Tartrate | Zolpidem Tartrate | 88 | 15 |
| Escitalopram Oxalate | Escitalopram Oxalate | 83 | 21 |
| Meloxicam | Meloxicam | 83 | 22 |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 82 | 15 |
| Mounjaro | Tirzepatide | 77 | 14 |
| Metoprolol Tartrate | Metoprolol Tartrate | 76 | 20 |
| Ibuprofen | Ibuprofen | 74 | 16 |
| Farxiga | Dapagliflozin Propanediol | 73 | 18 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 72 | 12 |
| Sertraline Hcl | Sertraline Hcl | 71 | 23 |
| Pravastatin Sodium | Pravastatin Sodium | 70 | 20 |
| Allopurinol | Allopurinol | 69 | 23 |
| Ozempic | Semaglutide | 69 | 15 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 64 | 18 |
| Tramadol Hcl | Tramadol Hcl | 64 | 20 |
| Eliquis | Apixaban | 63 | 13 |
| Carvedilol | Carvedilol | 54 | 15 |
| Celecoxib | Celecoxib | 53 | 16 |
| Ondansetron Odt | Ondansetron | 53 | 17 |
| Trulicity | Dulaglutide | 51 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 49 | 13 |
| Hydrochlorothiazide | Hydrochlorothiazide | 49 | 13 |
| Metoprolol Succinate | Metoprolol Succinate | 49 | 14 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 48 | 13 |
| Pantoprazole Sodium | Pantoprazole Sodium | 45 | 13 |
| Valsartan | Valsartan | 44 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 42 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 40 | 11 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 35 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 35 | suppressed |
| Atenolol | Atenolol | 34 | suppressed |
| Azithromycin | Azithromycin | 33 | 30 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 33 | 23 |
| Symbicort | Budesonide/Formoterol Fumarate | 32 | suppressed |
| Jardiance | Empagliflozin | 31 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 31 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 29 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 28 | 11 |
| Diclofenac Sodium | Diclofenac Sodium | 27 | suppressed |
| Prednisone | Prednisone | 27 | 26 |
| Tizanidine Hcl | Tizanidine Hcl | 27 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 27 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 25 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 25 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 24 | 18 |
| Famotidine | Famotidine | 24 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 24 | suppressed |
| Potassium Chloride | Potassium Chloride | 23 | suppressed |
| Xarelto | Rivaroxaban | 23 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 22 | 21 |
| Montelukast Sodium | Montelukast Sodium | 22 | suppressed |
| Rybelsus | Semaglutide | 22 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 22 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 21 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 21 | suppressed |
| Chlorthalidone | Chlorthalidone | 20 | suppressed |
| Diazepam | Diazepam | 20 | suppressed |
| Baclofen | Baclofen | 19 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 19 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 19 | suppressed |
| Levofloxacin | Levofloxacin | 18 | 14 |
| Ezetimibe | Ezetimibe | 17 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 17 | 12 |
| Promethazine Hcl | Promethazine Hcl | 17 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 16 | suppressed |
| Finasteride | Finasteride | 16 | suppressed |
| Novolin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 16 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 16 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 15 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 15 | 14 |
| Entresto | Sacubitril/Valsartan | 15 | suppressed |
| Topiramate | Topiramate | 15 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 14 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 14 | suppressed |
| Fluocinonide | Fluocinonide | 14 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 14 | 14 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 14 | 14 |
| Amitriptyline Hcl | Amitriptyline Hcl | 13 | suppressed |
| Fluconazole | Fluconazole | 13 | 11 |
| Metformin Hcl Er | Metformin Hcl | 13 | suppressed |
| Naproxen | Naproxen | 13 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 13 | suppressed |
| Digoxin | Digoxin | 12 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 12 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 12 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 12 | suppressed |
| Metolazone | Metolazone | 12 | suppressed |
| Novolog Flexpen | Insulin Aspart | 12 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 12 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 11 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 11 | suppressed |
| Gemfibrozil | Gemfibrozil | 11 | suppressed |
| Lovastatin | Lovastatin | 11 | suppressed |
| Nitroglycerin | Nitroglycerin | 11 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $136.86 · 8 records | Merck Sharp & Dohme LLC | CAPVAXIVE, Dexcom G6 Transmitter, ENTRESTO, FARXIGA, LEQVIO, VERQUVO, VRAYLAR | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Entresto play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error